This ACNB Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday

Comments
Loading...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

  • Goldman Sachs analyst James Quigley initiated coverage on Sanofi SNY with a Neutral rating and announced a price target of $65. Sanofi shares closed at $57.79 on Thursday. See how other analysts view this stock.
  • Raymond James analyst Daniel Tamayo initiated coverage on ACNB Corporation ACNB with an Outperform rating and announced a price target of $47. ACNB shares closed at $41.25 on Thursday. See how other analysts view this stock.
  • B. Riley Securities analyst Nick Giles initiated coverage on United States Antimony Corporation UAMY with a Buy rating and announced a price target of $3. United States Antimony shares closed at $1.79 on Thursday. See how other analysts view this stock.
  • Maxim Group analyst Jason McCarthy initiated coverage on Anixa Biosciences, Inc. ANIX with a Buy rating and announced a price target of $1. Anixa Biosciences shares closed at $3.15 on Thursday. See how other analysts view this stock.

Considering buying ACNB stock? Here’s what analysts think:

Read This Next:

Photo: Shutterstock

ACNB Logo
ACNBACNB Corp
$38.74-3.54%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
83.43
Growth
56.18
Quality
39.94
Value
-
Price Trend
Short
Medium
Long
Got Questions? Ask
Which analysts are optimistic about ACNB?
How might ACNB Corporation leverage its rating?
What factors could drive Sanofi's stock towards $65?
Which investors are considering United States Antimony after the Buy rating?
How could Anixa Biosciences recover after a $3.15 close?
What market trends favor ACNB's growth potential?
Are there market conditions that might impact UAMY stock?
What should investors monitor for Sanofi to hit its price target?
How might biotech stocks react to analyst ratings?
Which financial sectors could benefit from ACNB's upward trend?
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm

Posted In: